M A Dimopoulos

Summary

Affiliation: University of Athens
Country: Greece

Publications

  1. doi request reprint Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: a single institution experience
    A Bamias
    Department of Clinical Therapeutics, University of Athens, Athens, Greece
    Gynecol Oncol 123:37-42. 2011
  2. ncbi request reprint Thalidomide and dexamethasone combination for refractory multiple myeloma
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Greece
    Ann Oncol 12:991-5. 2001
  3. ncbi request reprint Imaging of myeloma bone disease--implications for staging, prognosis and follow-up
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens, School of Medicine, Greece
    Acta Oncol 39:823-7. 2000
  4. ncbi request reprint Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in stage III and IV ovarian carcinoma: long-term results of a phase II study
    C A Papadimitriou
    Department of Clinical Therapeutics, Alexandra Hospital, Athens University School of Medicine, Athens, Greece
    Cancer 89:1547-54. 2000
  5. ncbi request reprint Solitary plasmacytoma of bone and asymptomatic multiple myeloma
    M A Dimopoulos
    Departments of Clinical Therapeutics and Radiology, University of Athens School of Medicine, Athens, Greece
    Blood 96:2037-44. 2000
  6. ncbi request reprint Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study
    M A Dimopoulos
    Department of Clinical Therapeutics, Athens University School of Medicine, Greece
    Gynecol Oncol 78:52-7. 2000
  7. ncbi request reprint Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment
    E Efstathiou
    Department of Clinical Therapeutics, University of Athens School of Medicine, Haidari, Athens, Greece
    Urology 65:126-30. 2005
  8. doi request reprint The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis
    E Terpos
    Department of Hematology and Medical Research, 251 General Air Force Hospital, Athens, Greece
    Leukemia 22:2247-56. 2008
  9. doi request reprint The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Leukemia 27:423-9. 2013
  10. ncbi request reprint The impact of age in the outcome of patients with advanced or recurrent cervical cancer after platinum-based chemotherapy
    E Kastritis
    University of Athens, Department of Clinical Therapeutics, Alexandra Hospital, 31 Komninon St, Haidari, 124 62, Athens, Greece
    Gynecol Oncol 104:372-6. 2007

Detail Information

Publications75

  1. doi request reprint Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: a single institution experience
    A Bamias
    Department of Clinical Therapeutics, University of Athens, Athens, Greece
    Gynecol Oncol 123:37-42. 2011
    ..Early-stage epithelial ovarian cancer represents a prognostically heterogenous group. We studied prognostic factors in patients treated with adjuvant paclitaxel/carboplatin chemotherapy...
  2. ncbi request reprint Thalidomide and dexamethasone combination for refractory multiple myeloma
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Greece
    Ann Oncol 12:991-5. 2001
    ..We investigated the combination of thalidomide with dexamethasone as salvage treatment for heavily pretreated patients with multiple myeloma, in order to assess its efficacy and toxicity...
  3. ncbi request reprint Imaging of myeloma bone disease--implications for staging, prognosis and follow-up
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens, School of Medicine, Greece
    Acta Oncol 39:823-7. 2000
    ..Furthermore, magnetic resonance imaging contributes to the differential diagnosis of compression fractures in patients with myeloma and can be used for assessment of response to treatment...
  4. ncbi request reprint Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in stage III and IV ovarian carcinoma: long-term results of a phase II study
    C A Papadimitriou
    Department of Clinical Therapeutics, Alexandra Hospital, Athens University School of Medicine, Athens, Greece
    Cancer 89:1547-54. 2000
    ..Anthracyclines also have activity in this disease. We conducted a Phase II study by using the combination of paclitaxel, cisplatin, and epirubicin for the treatment of advanced ovarian carcinoma...
  5. ncbi request reprint Solitary plasmacytoma of bone and asymptomatic multiple myeloma
    M A Dimopoulos
    Departments of Clinical Therapeutics and Radiology, University of Athens School of Medicine, Athens, Greece
    Blood 96:2037-44. 2000
    ..In patients with either solitary plasmacytoma of bone or asymptomatic MM, systemic treatment should be deferred until there is evidence of disease progression...
  6. ncbi request reprint Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study
    M A Dimopoulos
    Department of Clinical Therapeutics, Athens University School of Medicine, Greece
    Gynecol Oncol 78:52-7. 2000
    ..We administered this combination to patients with metastatic or recurrent carcinoma of the endometrium to evaluate its activity and to define its toxicity...
  7. ncbi request reprint Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment
    E Efstathiou
    Department of Clinical Therapeutics, University of Athens School of Medicine, Haidari, Athens, Greece
    Urology 65:126-30. 2005
    ..In an effort to minimize toxicity, we designed an every-2-week docetaxel administration regimen with a 3-day low-dose EMP regimen. Patients with bone metastases also received zoledronic acid...
  8. doi request reprint The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis
    E Terpos
    Department of Hematology and Medical Research, 251 General Air Force Hospital, Athens, Greece
    Leukemia 22:2247-56. 2008
    ..We conclude that VMDT with intermittent thalidomide is an active and well-tolerated regimen for relapsed/refractory myeloma, affecting abnormal bone remodeling and angiogenesis...
  9. doi request reprint The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Leukemia 27:423-9. 2013
    ....
  10. ncbi request reprint The impact of age in the outcome of patients with advanced or recurrent cervical cancer after platinum-based chemotherapy
    E Kastritis
    University of Athens, Department of Clinical Therapeutics, Alexandra Hospital, 31 Komninon St, Haidari, 124 62, Athens, Greece
    Gynecol Oncol 104:372-6. 2007
    ..It is unknown whether these young patients have a poorer outcome compared to older patients or whether elderly patients have inferior outcome than younger patients when treated with combination chemotherapy...
  11. ncbi request reprint The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy
    A Bamias
    Department of Clinical Therapeutics, Medical School, University of Athens, 31 Komninon Street, Haidari, 12462 Athens, Greece
    Ann Oncol 16:307-13. 2005
    ..We compared the tolerability and efficacy of first-line platinum (cisplatin or carboplatin)-based chemotherapy in elderly patients (> or =70 years) with those in younger patients...
  12. doi request reprint VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT
    E Terpos
    Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
    Leukemia 28:928-34. 2014
    ....
  13. ncbi request reprint Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer
    G Aravantinos
    Hellenic Co operative Oncology Group, Athens, Greece
    Ann Oncol 14:1094-9. 2003
    ..This multicenter, prospective phase II study evaluated the safety and efficacy of the combination of docetaxel and vinorelbine in patients with platinum-resistant, paclitaxel-pretreated recurrent ovarian cancer...
  14. ncbi request reprint Ifosfamide, paclitaxel and cisplatin first-line chemotherapy in advanced, suboptimally debulked epithelial ovarian cancer
    C A Papadimitriou
    Department of Clinical Therapeutics, Alexandra Hospital, Athens University School of Medicine, Tatoiou 146, 146 71 Nea Erythrea, Athens, Greece
    Cancer 92:1856-63. 2001
    ..We conducted a Phase II study with the combination of ifosfamide, paclitaxel, and cisplatin for the treatment of newly diagnosed patients with advanced, suboptimally debulked ovarian carcinoma...
  15. ncbi request reprint Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer
    G Aravantinos
    Hellenic Co operative Oncology Group, Athens, Greece
    Ann Oncol 11:607-12. 2000
    ..The prognosis of platinum resistant ovarian cancer is very poor and the treatment of choice has not been clearly defined...
  16. ncbi request reprint Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study
    G Aravantinos
    Agii Anargiri Cancer Hospital, Athens, Greece
    Ann Oncol 16:1116-22. 2005
    ..The two platinum derivatives have been previously combined as they are not totally cross-resistant and as they share no overlapping toxicities...
  17. ncbi request reprint Anthracycline-based adjuvant chemotherapy in early-stage uterine sarcomas: long-term results of a single institution experience
    C A Papadimitriou
    Department of Clinical Therapeutics, Alexandra Hospital, Athens University School of Medicine, Athens, Greece
    Eur J Gynaecol Oncol 28:109-16. 2007
    ..Uterine sarcomas are rare neoplasms characterized by a high rate of local recurrences and distant metastases. The role of chemotherapy in early-stage completely resected disease remains controversial...
  18. ncbi request reprint High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: results of a single-institution randomized trial
    C Papadimitriou
    Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, Athens, Greece
    Bone Marrow Transplant 41:547-54. 2008
    ..In an intent-to-treat analysis, there were no significant differences between the two arms in TTP (P=0.059) as well as in overall survival (OS) (P=0.38)...
  19. doi request reprint Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)
    E Kastritis
    Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, Athens, Greece
    Leukemia 23:1152-7. 2009
    ..001). ISS was also valid in patients who actually received upfront treatment with novel drugs (4-year survival rate was 85, 61 and 26% for ISS stage I, II and III patients, P=0.001)...
  20. doi request reprint Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)
    A Bamias
    Department of Clinical Therapeutics, Alexandra Hospital, Athens University Medical School, Athens, Greece
    Ann Oncol 24:1011-7. 2013
    ..However, the role of GC intensification has not been studied. We conducted a randomized, phase III study comparing a DD-GC regimen with DD-MVAC in advanced UC...
  21. ncbi request reprint Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG)
    G Papaxoinis
    Second Department of Internal Medicine, University General Hospital Attikon, University of Athens, Haidari, Greece
    Ann Oncol 19:780-6. 2008
    ..The aim was to examine characteristics and treatment results of patients with mucosa-associated lymphoid tissue (MALT) non-Hodgkin's lymphomas...
  22. ncbi request reprint Adjuvant chemotherapy with paclitaxel and carboplatin in non-endometrioid carcinoma of the uterus
    G T Bozas
    Department of Clinical Therapeutics, University of Athens, Alexandra Hospital, Greece
    Eur J Gynaecol Oncol 26:627-31. 2005
    ..The aim of this study was to investigate the activity and safety of paclitaxel/carboplatin chemotherapy as the only adjuvant treatment in patients with surgically resected UPSC and UCCC...
  23. ncbi request reprint Brain metastases as isolated site of relapse in patients with epithelial ovarian cancer previously treated with platinum and paclitaxel-based chemotherapy
    E Kastritis
    Department of Clinical Therapeutics, Alexandra Hospital, Athens University School of Medicine, Athens, Greece
    Int J Gynecol Cancer 16:994-9. 2006
    ..Patients with isolated brain metastases have comparable survival to patients with relapse outside the CNS, and long-term remission can be achieved in some cases, provided that systemic chemotherapy is added to local treatment...
  24. ncbi request reprint Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group
    D Pectasides
    Second Department of Internal Medicine Propaedeutic, Oncology Section, University General Hospital Attikon, Athens, Greece
    Lung Cancer 58:355-61. 2007
    ..The purpose of this study was to evaluate the efficacy and toxicity of cisplatin, etoposide and irinotecan as first-line treatment in patients with extensive small-cell lung cancer (E-SCLC)...
  25. doi request reprint Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG)
    P A Kosmidis
    Department of Medical Oncology, Hygeia Hospital, Athens, Greece
    Ann Oncol 22:827-34. 2011
    ..This combination was compared prospectively with the paclitaxel/gemcitabine regimen in non-operable non-small-cell lung cancer...
  26. doi request reprint A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer
    Aristotelis Bamias
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Cancer Chemother Pharmacol 65:1009-21. 2010
    ..However, the possibility that a benefit by the addition of RT was not detected due to decreased power of the study should not be excluded...
  27. ncbi request reprint Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group
    A Bamias
    Department of Clinical TherapeuticsUniversity of Athens, School of Medicine, Athens, Greece
    J Clin Oncol 22:2150-4. 2004
    ..We prospectively studied a cohort of patients who underwent surgery for high-risk carcinoma of the upper urinary tract to assess the feasibility of the combination of paclitaxel and carboplatin as adjuvant treatment...
  28. doi request reprint Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Leukemia 24:1769-78. 2010
    ..The outcome of patients with del17p remains extremely poor even with VRD combination...
  29. ncbi request reprint Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group
    A Bamias
    Department of Clinical Therapeutics Urology, Hygiene and Epidemiology, University of Athens School of Medicine, Athens, Greece
    J Clin Oncol 22:220-8. 2004
    ..The toxicity of this regimen compared favorably with that reported for MVAC. We thus designed a randomized phase III trial to compare DC with MVAC...
  30. ncbi request reprint Carboplatin hypersensitivity reactions: a single institution experience
    M P Zorzou
    Department of Clinical Therapeutics, Medical School, University of Athens, Athens, Greece
    J Chemother 17:104-10. 2005
    ..In conclusion, pretreatment with corticosteroids, antihistamines and a slower infusion rate may make re-treatment possible in patients having experienced hypersensitivity to carboplatin...
  31. doi request reprint Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents
    M A Dimopoulos
    Greek Myeloma Study Group, Athens, Greece
    Ann Oncol 25:195-200. 2014
    ....
  32. ncbi request reprint Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group
    P A Kosmidis
    Department of Medical Oncology, Hygeia Hospital, Athens, Greece
    Ann Oncol 19:115-22. 2008
    ..This phase III study was designed to compare the combination paclitaxel (Taxol)-gemcitabine (PG) versus carboplatin-gemcitabine (CG) in patients with advanced inoperable non-small-cell lung cancer...
  33. ncbi request reprint Treatment of Waldenstrom's macroglobulinemia with thalidomide
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Greece
    J Clin Oncol 19:3596-601. 2001
    ..We performed a prospective phase II study to assess the activity of thalidomide in patients with Waldenstrom's macroglobulinemia (WM)...
  34. ncbi request reprint The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy
    E Kastritis
    Department of Clinical Therapeutics, Alexandra Hospital, Athens University School of Medicine, 31 Komninon Street, Haidari, 124 62 Athens, Greece
    Gynecol Oncol 99:376-82. 2005
    ..We compared the outcome of patients with non-squamous with that of squamous cell carcinomas after platinum-based combination chemotherapy as first line therapy for stage IV or recurrent cervical carcinoma...
  35. doi request reprint Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid
    M A Dimopoulos
    Department of Clinical Therapeutics, Medical School, University of Athens, Greece
    Ann Oncol 20:117-20. 2009
    ..We investigated whether the occurrence of ONJ decreased after the implementation of preventive measures in 128 patients with MM who received zoledronic acid...
  36. ncbi request reprint Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial
    V Georgoulias
    Department of Medical Oncology, School of Medicine, University of Crete, Heraklion, Greece
    J Clin Oncol 17:914-20. 1999
    ..To evaluate the tolerance and efficacy of the combination of docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer (NSCLC)...
  37. doi request reprint Paclitaxel chemotherapy and vascular toxicity as assessed by flow-mediated and nitrate-mediated vasodilatation
    M Vassilakopoulou
    Department of Clinical Therapeutics, University of Athens School of Medicine, Alexandra Hospital, Athens, Greece
    Vascul Pharmacol 53:115-21. 2010
    ..Antitumor activity of paclitaxel is based on promotion of abnormal microtubule (MT) assembly but it is also considered to have significant pro-inflammatory and anti-angiogenic effects in vivo and thus may cause vascular dysfunction...
  38. doi request reprint Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease
    E Kastritis
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Leukemia 27:947-53. 2013
    ....
  39. ncbi request reprint Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy
    E Terpos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Ann Oncol 23:2681-6. 2012
    ..Activin-A is a transforming growth factor -β superfamily member, which seems to be implicated in the biology of osteolytic disease in multiple myeloma...
  40. ncbi request reprint Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Ann Oncol 14:1299-305. 2003
    ..Although several studies have evaluated possible prognostic factors of this disease, few have focused on the survival and prognosis of symptomatic patients after the initiation of treatment...
  41. ncbi request reprint Epithelial ovarian cancer in Greece: a retrospective study of 1,791 patients by the Hellenic Cooperative Oncology Group (HeCOG)
    D Pectasides
    2nd Department of Internal Medicine, Propaedeutic, Oncology Section, Attikon University Hospital, Rimini 1, Haidari, Athens, Greece
    Anticancer Res 29:745-51. 2009
    ..The aim of this retrospective study was to present the epidemiological, pathological and clinical characteristics and treatment results of Greek women with epithelial ovarian cancer (EOC)...
  42. doi request reprint Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study
    G Mountzios
    Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, Athens, Greece
    Ann Oncol 20:1362-8. 2009
    ....
  43. ncbi request reprint Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study
    K Zervas
    Greek Myeloma Study Group, Athens, Greece
    Ann Oncol 15:134-8. 2004
    ....
  44. ncbi request reprint Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma
    L A Moulopoulos
    Department of Radiology and Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Ann Oncol 16:1824-8. 2005
    ..Magnetic resonance imaging (MRI) has been a useful technique for the assessment of patients with multiple myeloma (MM). We evaluated the prognostic significance of different MRI patterns in symptomatic patients with MM...
  45. ncbi request reprint Neoadjuvant chemotherapy with docetaxel and cisplatin in patients with high-risk resectable bladder carcinoma: long term results
    A Bamias
    Department of Clinical Therapeutics, University of Athens, School of Medicine, Greece
    Eur Urol 46:344-50; discussion 350-1. 2004
    ..We are reporting the results of a phase II study using this combination as neoadjuvant treatment in patients with muscle invasive bladder cancer...
  46. doi request reprint Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: cell type is the most useful prognostic factor
    A Bamias
    Dept of Clinical Therapeutics, Medical School, University of Athens, Athens, Greece
    Eur J Cancer 48:1476-83. 2012
    ..Ovarian carcinomas have been classified into types I and II according to the hypothesised mode of carcinogenesis and molecular characteristics. The prognostic significance of this classification has not been studied...
  47. ncbi request reprint Epithelial ovarian carcinoma in younger vs older women: is age an independent prognostic factor? The Hellenic Oncology Cooperative Group experience
    D Pectasides
    Second Department of Internal Medicine, Oncology Section, University General Hospital Attikon, Athens, Greece
    Int J Gynecol Cancer 17:1003-10. 2007
    ..001). In conclusion, younger women with EOC have significantly improved survival compared to older patients. Age, PS, stage of the disease at diagnosis, and residual disease are important independent predictors for survival...
  48. ncbi request reprint Microvessel density (MVD) and cyclooxygenase-2 (COX-2)/ beta-catenin interaction are associated with relapse in patients with transitional carcinoma receiving adjuvant chemotherapy with paclitaxel/carboplatin: a hellenic cooperative oncology group (HECOG)
    A Bamias
    Department of Clinical Therapeutics, Medical School, University of Athens, Greece
    Anticancer Res 28:2479-86. 2008
    ..Cycloxygenase (COX)-2 has been associated with proliferation, apoptosis and angiogenesis in urothelial cancer. The prognostic significance of COX-2 in patients who received adjuvant chemotherapy for urothelial cancer was examined...
  49. doi request reprint Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Leukemia 23:2147-52. 2009
    ..Low beta(2)-microglobulin and low bone marrow plasmacytosis were associated with longer survival. In conclusion, these data confirm the significant response and survival benefit with lenalidomide and dexamethasone...
  50. ncbi request reprint Sunitinib treatment in patients with severe renal function impairment: a report of four cases by the Hellenic Cooperative Oncology Group
    G Lainakis
    Department of Clinical Therapeutics, University of Athens, Medical School, Athens
    Clin Nephrol 72:73-8. 2009
    ..We conclude that sunitinib can be administered to the majority of patients with RCC and significant renal function impairment...
  51. ncbi request reprint Renal failure in multiple myeloma: incidence, correlations, and prognostic significance
    V Eleutherakis-Papaiakovou
    Department of Clinical Therapeutics, University of Athens, School of Medicine, Greece
    Leuk Lymphoma 48:337-41. 2007
    ..When corrected for stage, renal failure had no impact on survival...
  52. ncbi request reprint Clinicopathological features of primary fallopian tube carcinoma: a single institution experience
    C A Papadimitriou
    Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, Greece
    Eur J Gynaecol Oncol 30:389-95. 2009
    ..Primary fallopian tube carcinoma (PFTC) is a rare malignancy with only few data existing on the impact of prognostic factors...
  53. ncbi request reprint Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy
    Aristotelis Bamias
    Department of Clinical Therapeutics, Medical School, University of Athens, Greece
    Gynecol Oncol 108:421-7. 2008
    ..We have investigated the association of cytokines in the ascites from patients with ovarian cancer with these populations, the platinum resistance and the prognosis of these patients...
  54. doi request reprint The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer
    A Bamias
    Department of Clinical Therapeutics, University of Athens, Medical School, Greece
    Eur J Cancer 47:1660-8. 2011
    ....
  55. doi request reprint Treatment of plasma cell dyscrasias with lenalidomide
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens, School of Medicine, Athens, Greece
    Leukemia 22:1343-53. 2008
    ..In this review, we summarize the mechanisms of action, toxicity and clinical activity, and the current role of lenalidomide in patients with multiple myeloma or other related plasma cell disorders...
  56. pmc High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma
    E Terpos
    Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
    Blood Cancer J 6:e482. 2016
    ..These results support an important role of periostin in the biology of myeloma and reveal periostin as a possible target for the development of antimyeloma drugs...
  57. doi request reprint Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma
    E Kastritis
    Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
    Leukemia 28:2075-9. 2014
    ..In conclusion, preservation of uninvolved immunoglobulins in newly diagnosed patients with symptomatic MM was independently associated with long term disease control and improved survival. ..
  58. pmc VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2
    N G Gavalas
    Department of Clinical Therapeutics, Medical School, University of Athens, Alexandra Hospital, 80 Vas Sofias Avenue, 115 28 Athens, Greece
    Br J Cancer 107:1869-75. 2012
    ..We sought to investigate the possible direct effect of VEGF on T-cell activation and through which type of VEGF receptor it exerts this effect on cells isolated from ovarian cancer patients' ascites...
  59. ncbi request reprint Late relapse of epithelial ovarian cancer: a single institution experience
    A Bamias
    Department of Clinical Therapeutics, University of Athens, School of Medicine, Athens, Greece
    Eur J Gynaecol Oncol 26:439-42. 2005
    ..Late relapses are infrequent in ovarian cancer. We present the characteristics and outcome of patients who relapsed at least five years after first-line chemotherapy...
  60. pmc Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Alexandra Hospital, Athens, Greece
    Leukemia 25:1620-6. 2011
    ..Thereafter, patients may benefit from lower-dose continued therapy; prospective studies are needed to confirm these findings...
  61. ncbi request reprint Anthracycline-based chemotherapy of primary non-Hodgkin's lymphoma of the testis: the hellenic cooperative oncology group experience
    D Pectasides
    Hellenic Cooperative Oncology Group HeCoG, Athens, Greece
    Oncology 58:286-92. 2000
    ..Because the relapse rate in the CNS and contralateral testis is quite high in most studies, prophylactic CNS treatment and radiotherapy to the other testis should be included in the management of testicular lymphoma...
  62. ncbi request reprint The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group
    G F Samelis
    Hippokration General Hospital, Athens, Greece
    Urology 61:1211-5. 2003
    ..The survival of patients with prostate cancer who relapse after androgen ablation is limited and the therapeutic options are restricted...
  63. doi request reprint Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis
    M Gkotzamanidou
    1 Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA 2 Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Leukemia 28:1113-21. 2014
    ..0003). We conclude that progressive changes in chromatin structure, transcriptional activity and DDR pathways during myelomagenesis occur in malignant plasma cells and that these changes are also reflected in PBMCs. ..
  64. ncbi request reprint The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma
    E Terpos
    Department of Hematology and Medical Research, 251 General Air Force Hospital, Athens, Greece
    Leukemia 21:1875-84. 2007
    ..This review summarizes all available data for these attractive agents that combine potent anti-myeloma activity with beneficial effects on bone and may alter the way of management of myeloma-related bone disease...
  65. pmc Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration
    A Bamias
    Department of Clinical Therapeutics, University of Athens, Athens, Greece
    Br J Cancer 109:332-41. 2013
    ..We developed and externally validated a simple model for overall survival (OS) in mRCC. We also studied the recently validated International Database Consortium (IDC) model in our data sets...
  66. doi request reprint The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function
    M A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Greece
    Ann Oncol 23:722-9. 2012
    ....
  67. ncbi request reprint Molecular markers in epithelial ovarian cancer: their role in prognosis and therapy
    F Zagouri
    Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, Athens, Greece
    Eur J Gynaecol Oncol 31:268-77. 2010
    ..It is tempting to anticipate the gradual integration of molecular profiling in clinical practice...
  68. ncbi request reprint Treatment of intermediate and advanced stage Hodgkin's disease with modified baseline BEACOPP regimen: a Hellenic Co-operative Oncology Group Study
    T Economopoulos
    Second Department of Internal Medicine Propaedeutic, Evangelismos Hospital, Athens University, Athens, Greece
    Eur J Haematol 71:257-62. 2003
    ..Further follow up time is required to evaluate long-term toxicity...
  69. ncbi request reprint Reverse of the differential uptake intensity of Tc-99m MIBI and Tc-99m V-DMSA by multiple myeloma lesions in response to therapy
    T Athanasoulis
    Department of Nuclear Medicine Alexandra University Hospital, Athens, Greece
    Clin Nucl Med 28:631-5. 2003
    ....
  70. ncbi request reprint A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment
    I Dimopoulou
    Department of Pulmonary and Critical Care Medicine, Evangelismos Hospital, Athens, Greece
    Ann Oncol 15:1250-5. 2004
    ..However, a prospective evaluation of cancer patients treated with gemcitabine-based chemotherapy without neoplastic involvement of the thorax and without administration of radiotherapy has not been performed...
  71. ncbi request reprint The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio
    E Terpos
    Department of Hematology, 251 General Airforce Hospital, Athens, Greece
    Leukemia 19:1969-76. 2005
    ..These results suggest that the combination of intermediate dose of Thal/Dex is effective in patients with refractory/relapsed myeloma and improves abnormal bone remodeling through the reduction of sRANKL/OPG ratio...
  72. ncbi request reprint Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma
    M A Dimopoulos
    Department of Clinical Therapeutics and Internal Medicine, University of Athens School of Medicine, Athens, Greece
    Ann Oncol 14:1039-44. 2003
    ..We designed a prospective randomized study to compare the objective response rates of two VAD-like outpatient regimens as primary treatment for symptomatic patients with multiple myeloma...
  73. ncbi request reprint Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance
    A Bamias
    Department of Clinical Therapeutics, University of Athens, Greece
    Gynecol Oncol 106:75-81. 2007
    ..We performed a prospective study of T lymphocytes isolated from ascites from patients with ovarian carcinoma and we compared them with the respective populations in blood and tumors...
  74. doi request reprint Low frequency of somatic mutations in uterine sarcomas: a molecular analysis and review of the literature
    S Murray
    Department of Molecular Biology and Genetics, Metropolitan Hospital, Athens, Greece
    Mutat Res 686:68-73. 2010
    ....
  75. doi request reprint The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group
    E Terpos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Alexandra General Hospital, Athens, Greece
    Leukemia 24:1700-12. 2010
    ....